Keith J. Benkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith J. Benkov has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Anne M. Griffiths
IBD Centre, The Hospital for Sick Children, Department of Pediatrics, Faculty of Medicine, University of Toronto
6 shared publications - Anthony Roger Otley
Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
6 shared publications Ashish S. Patel
6 shared publicationsDavid J. Keljo
6 shared publications- David R. Mack
Division of Gastroenterology, Hepatology & Nutrition, Children’s Hospital of Eastern Ontario and University of Ottawa
6 shared publications David Ziring
6 shared publications
Latest Publications
- 18 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1076-1086
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease
INTRODUCTION: Human leukocyte antigen (HLA) DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNFα) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data. METHODS: We analyzed banked serum from patients with CD aged P = 0.08). After stratification by HLA DQA1*05 and by methotrexate vs placebo, patients who were HLA DQA1*05 negative and assigned to methotrexate experienced less treatment failures than HLA DQA1*05-positive patients on placebo (hazard ratio 0.31, 95% CI 0.13–0.70; P = 0.005). A trend toward increased ADA development among HLA DQA1*05-positive participants was not significant (odds ratio 1.96, 95% CI 0.90–4.31, P = 0.09). After further stratification, HLA DQA1*05-negative participants assigned to methotrexate were less likely to develop ADA relative to HLA DQA1*05-positive patients on placebo (odds ratio 0.12, 95% CI 0.03–0.55; P = 0.008). DISCUSSION: In a randomized trial of children with CD initiating anti-TNFα, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.
- 18 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (5) , 1076-1086
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease
INTRODUCTION: Human leukocyte antigen (HLA) DQA1*05 has been associated with the development of anti-drug antibodies (ADA) to tumor necrosis factor antagonists (anti-TNFα) and treatment failure among adults with Crohn's disease (CD). However, findings from other studies have been inconsistent with limited pediatric data. METHODS: We analyzed banked serum from patients with CD aged P = 0.08). After stratification by HLA DQA1*05 and by methotrexate vs placebo, patients who were HLA DQA1*05 negative and assigned to methotrexate experienced less treatment failures than HLA DQA1*05-positive patients on placebo (hazard ratio 0.31, 95% CI 0.13–0.70; P = 0.005). A trend toward increased ADA development among HLA DQA1*05-positive participants was not significant (odds ratio 1.96, 95% CI 0.90–4.31, P = 0.09). After further stratification, HLA DQA1*05-negative participants assigned to methotrexate were less likely to develop ADA relative to HLA DQA1*05-positive patients on placebo (odds ratio 0.12, 95% CI 0.03–0.55; P = 0.008). DISCUSSION: In a randomized trial of children with CD initiating anti-TNFα, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification.
- 6 March 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (6) , 1110-1116
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
INTRODUCTION: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI). METHODS: The COMBINE trial compared anti-TNF monotherapy with combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI vs BMI Z-score >1, adjusting for prescribed anti-TNF (infliximab [IFX] or adalimumab [ADA]), trial treatment assignment (combination vs monotherapy), and relevant covariates. Median anti-TNF levels across BMI category was also examined. RESULTS: Of 224 participants (162 IFX initiators and 62 ADA initiators), 111 (81%) had a normal BMI and 43 (19%) had a high BMI. High BMI was associated with treatment failure among ADA initiators (7/10 [70%] vs 12/52 [23%], hazard ratio 0.29, P = 0.007) but not IFX initiators. In addition, ADA-treated patients with a high BMI had lower ADA levels compared with those with normal BMI (median 5.8 vs 12.8 μg/mL, P = 0.02). IFX trough levels did not differ between BMI groups. DISCUSSION: Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.
- 6 March 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (6) , 1110-1116
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn’s Disease
INTRODUCTION: Obesity is common among patients with pediatric Crohn's disease (PCD). Some adult studies suggest obese patients respond less well to anti-tumor necrosis factor (TNF) treatment. This study sought compares anti-TNF response and anti-TNF levels between pediatric patients with normal and high body mass index (BMI). METHODS: The COMBINE trial compared anti-TNF monotherapy with combination therapy with methotrexate in patients with PCD. In this secondary analysis, a comparison of time-to-treatment failure among patients with normal BMI vs BMI Z-score >1, adjusting for prescribed anti-TNF (infliximab [IFX] or adalimumab [ADA]), trial treatment assignment (combination vs monotherapy), and relevant covariates. Median anti-TNF levels across BMI category was also examined. RESULTS: Of 224 participants (162 IFX initiators and 62 ADA initiators), 111 (81%) had a normal BMI and 43 (19%) had a high BMI. High BMI was associated with treatment failure among ADA initiators (7/10 [70%] vs 12/52 [23%], hazard ratio 0.29, P = 0.007) but not IFX initiators. In addition, ADA-treated patients with a high BMI had lower ADA levels compared with those with normal BMI (median 5.8 vs 12.8 μg/mL, P = 0.02). IFX trough levels did not differ between BMI groups. DISCUSSION: Overweight and obese patients with PCD are more likely to experience ADA treatment failure than those with normal BMI. Higher BMI was associated with lower drug trough levels. Standard ADA dosing may be insufficient for overweight children with PCD. Among IFX initiators, there was no observed difference in clinical outcomes or drug levels, perhaps due to weight-based dosing and/or greater use of proactive drug monitoring.
- Open Access
- 24 January 2019
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 7 (1) , 51
Implementing a Novel Quality Improvement-Based Approach to Data Quality Monitoring and Enhancement in a Multipurpose Clinical Registry
Objective: To implement a quality improvement based system to measure and improve data quality in an observational clinical registry to support a Learning Healthcare System.Data Source: ImproveCareNow Network registry, which as of September 2019 contained data from 314,250 visits of 43,305 pediatric Inflammatory Bowel Disease (IBD) patients at 109 participating care centers.Study Design: The impact of data quality improvement support to care centers was evaluated using statistical process control methodology. Data quality measures were defined, performance feedback of those measures using statistical process control charts was implemented, and reports that identified data items not following data quality checks were developed to enable centers to monitor and improve the quality of their data.Principal Findings: There was a pattern of improvement across measures of data quality. The proportion of visits with complete critical data increased from 72 percent to 82 percent. The percent of registered patients improved from 59 percent to 83 percent. Of three additional measures of data consistency and timeliness, one improved performance from 42 percent to 63 percent. Performance declined on one measure due to changes in network documentation practices and maturation. There was variation among care centers in data quality.Conclusions: A quality improvement based approach to data quality monitoring and improvement is feasible and effective.
- 24 January 2019
- Published by Ubiquity Press, Ltd. in eGEMs (Generating Evidence & Methods to improve patient outcomes)
- Vol. 7 (1) , 51
Open AccessImplementing a Novel Quality Improvement-Based Approach to Data Quality Monitoring and Enhancement in a Multipurpose Clinical Registry
Objective: To implement a quality improvement based system to measure and improve data quality in an observational clinical registry to support a Learning Healthcare System.Data Source: ImproveCareNow Network registry, which as of September 2019 contained data from 314,250 visits of 43,305 pediatric Inflammatory Bowel Disease (IBD) patients at 109 participating care centers.Study Design: The impact of data quality improvement support to care centers was evaluated using statistical process control methodology. Data quality measures were defined, performance feedback of those measures using statistical process control charts was implemented, and reports that identified data items not following data quality checks were developed to enable centers to monitor and improve the quality of their data.Principal Findings: There was a pattern of improvement across measures of data quality. The proportion of visits with complete critical data increased from 72 percent to 82 percent. The percent of registered patients improved from 59 percent to 83 percent. Of three additional measures of data consistency and timeliness, one improved performance from 42 percent to 63 percent. Performance declined on one measure due to changes in network documentation practices and maturation. There was variation among care centers in data quality.Conclusions: A quality improvement based approach to data quality monitoring and improvement is feasible and effective.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su2017 - Predicting Response to Standardized Pediatric Colitis Therapy: The Protect Study
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su2017 - Predicting Response to Standardized Pediatric Colitis Therapy: The Protect Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S172-S173
Microbial Dysbiosis Associated with Disease Severity in Treatment Naive Pediatric Patients with New-Onset Ulcerative Colitis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S172-S173
Microbial Dysbiosis Associated with Disease Severity in Treatment Naive Pediatric Patients with New-Onset Ulcerative Colitis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S201
Suboptimal Early Outcomes following Standardized Induction Therapy in Children Newly Diagnosed with Ulcerative Colitis: The Protect Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S201
Suboptimal Early Outcomes following Standardized Induction Therapy in Children Newly Diagnosed with Ulcerative Colitis: The Protect Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S954
Greater Contribution of HLA to Risk for Pediatric-Onset Ulcerative Colitis Can be Narrowed to 3 Independent Classic HLA Variants and Corresponding Amino Acid Changes
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S954
Greater Contribution of HLA to Risk for Pediatric-Onset Ulcerative Colitis Can be Narrowed to 3 Independent Classic HLA Variants and Corresponding Amino Acid Changes
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S133
634 Serologic Reactivity Reflects Clinical and Genetic Expression of Ulcerative Colitis in Children. The Protect Study
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S133
634 Serologic Reactivity Reflects Clinical and Genetic Expression of Ulcerative Colitis in Children. The Protect Study
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S588
Su1919 The Use of Concomitant Immunomodulators With Adalimumab Therapy in Pediatric Crohn's Disease
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S588
Su1919 The Use of Concomitant Immunomodulators With Adalimumab Therapy in Pediatric Crohn's Disease
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB141
441 Endoscopic Assessment of Mucosal Activity in Pediatric Ulcerative Colitis: Are Current Methods Reliable?
- 1 May 2014
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 79 (5) , AB141
441 Endoscopic Assessment of Mucosal Activity in Pediatric Ulcerative Colitis: Are Current Methods Reliable?